Providers/Grant Support
Provided by ASHP.
This activity is supported by an educational grant from Merck.
Credits Available
- Physicians — maximum of 1.5 AMA PRA Category 1 Credits™
- Nurses — 1.5 Nursing Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Pharmacists may earn 1.5 CPE credits (0.15 CEUs) by creating a free account and completing this course at elearning.ashp.org. Your certificate will save on elearning.ashp.org and will not be included in your FreeCME Dashboard. CPE will be reported directly to CPE Monitor (be prepared to provide your NABP eProfile ID and birth month and date and to claim CE within 60 days of completion).
Important note for Pharmacists ONLY--DO NOT CONTINUE on FreeCME: To earn Pharmacy CE, Pharmacists must take this activity on elearning.ashp.org. Please follow that link to access the activity.
Target Audience
This activity is designed to meet the educational needs of pharmacists, oncology and non-oncology physicians, physician associates, nurse practitioners and nurses who practice in hospitals, health systems, ambulatory clinics, and infusion centers who care for or are interested in the care of patients treated with immune checkpoint inhibitors.
Program Overview
This activity will cover patients taking immune checkpoint inhibitors (ICIs) are seen throughout all practice settings due to their impact on cancer survival and indications throughout many cancer types. ICIs have the potential to cause immune-related adverse events (irAEs), which can be a diagnostic and therapeutic challenge. This activity will discuss early identification and management irAEs to prevent progression leading to severe adverse effects and to avoid interruptions in life-prolonging ICI therapy. It is imperative that physicians, pharmacists, physician associates, nurse practitioners and nurses apply evidence-based guideline recommendations to patient-specific care plans to improve overall patient outcomes.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Describe mechanisms of action of immune checkpoint inhibitors (ICIs) and how they relate to the pathophysiology of immune-related adverse events (irAEs).
- Determine best methods to address potential ICI drug interactions based on current and emerging data.
- Evaluate strategies for diagnosis and management of irAEs.
- Develop interprofessional, evidence-based care plans for patients receiving ICIs who require irAE management taking into account patient-specific factors
Faculty
Jordan McPherson, PharmD, MS, BCOP
Activity Chair
Oncology Pharmacy Manager
Clinical Pharmacist, Melanoma & Skin Cancer
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah
Pauline Funchain, MD
Associate Professor
Stanford University
Stanford, California
Marianne Davies, DNP, ACNP, AOCNP, FAAN
Program Manager, Care Signature Pathway & Senior Oncology Nurse Practitioner
Yale New Haven Hospital
Associate Professor
Yale University-School of Nursing
New Haven, Connecticut
Accreditation Statement
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
The American Society of Health-System Pharmacists designates this enduring activity for a maximum of 1.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Disclosure of Conflict of Interest
Pauline Funchain
- Research Grant: Ideaya, Linneaus
- Consultant: Immunocore, Sanofi
- Advisor: Tempus
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be immediately available the participant.
Important note for Pharmacists ONLY--DO NOT CONTINUE on FreeCME: To earn Pharmacy CE, Pharmacists must take this activity on elearning.ashp.org. Please follow that link to access the activity.
Disclosure of Unlabeled Use
The American Society of Health-System Pharmacists requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected]